Improved diabetes control, allowing insulin cessation, after direct acting antiviral treatment (DAAT) of hepatitis C.

Authors :: Surendran A
Bhalla A
Whyte MB
Source :: BMJ case reports [BMJ Case Rep] 2022 Apr 21; Vol. 15 (4). Date of Electronic Publication: 2022 Apr 21.
Publication Year :: 2022
Abstract: There is a bidirectional relationship between hepatitis C and type 2 diabetes. The risk for developing type 2 diabetes is increased in patients with chronic hepatitis C virus (HCV) infection-with the prevalence of diabetes ranging from 13% to 33%. This is likely underpinned by insulin resistance. Type 2 diabetes may also be a predisposing factor for HCV infection. The new non-interferon-based therapeutic regimens for hepatitis C have transformed care and can eradicate disease. In this report, we show how such a regimen eradicated viral load, improved hepatocellular blood markers and significantly improved dysglycaemia, such that all glucose-lowering medication could be stopped.<br />Competing Interests: Competing interests: None declared.<br /> (© BMJ Publishing Group Limited 2022. No commercial re-use. See rights and permissions. Published by BMJ.)

Subjects :: Antiviral Agents therapeutic use
Hepacivirus genetics
Humans
Insulin therapeutic use
Diabetes Mellitus, Type 2 complications
Diabetes Mellitus, Type 2 drug therapy
Diabetes Mellitus, Type 2 epidemiology
Hepatitis C drug therapy
Hepatitis C, Chronic complications
Hepatitis C, Chronic drug therapy

Full Text Access

Tools